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Creatine kinase (CK) and lactate dehydrogenase (LDH) are widely used markers of tissue
damage. To search for sequence variants influencing serum levels of CK and LDH, 28.3 million
sequence variants identified through whole-genome sequencing of 2,636 Icelanders were
imputed into 63,159 and 98,585 people with CK and LDH measurements, respectively. Here
we describe 13 variants associating with serum CK and 16 with LDH levels, including four that
associate with both. Among those, 15 are non-synonymous variants and 12 have a minor
allele frequency below 5%. We report sequence variants in genes encoding the enzymes
being measured (CKM and LDHA), as well as in genes linked to muscular (ANO5) and
immune/inflammatory function (CD163/CD163L1, CSF1, CFH, HLA-DQB1, LILRB5, NINJ1 and
STAB1). A number of the genes are linked to the mononuclear/phagocyte system
and clearance of enzymes from the serum. This highlights the variety in the sources of normal
diversity in serum levels of enzymes.
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T
he release of intracellular enzymes into the serum is an
indicator of tissue damage and physiological cell turnover.
Thus, measurements of intracellular enzymes in serum are
widely used to diagnose tissue damage, monitor its course and
severity and gauge the effect of therapy.
Creatine kinase (CK) is an enzyme, catalyzing the ATP-
dependent phosphorylation of creatine that is important for
energy buffering in tissues with variable energy demands, most
notably skeletal and cardiac muscle1. Elevated serum CK levels
can indicate tissue damage, and are observed in a number of
pathological conditions, including statin-induced myopathy2.
Monitoring changes in serum CK levels is therefore important
in statin-treated patients who display muscle pain or weakness3,
and in patients deemed at risk of rhabdomyolysis for various
reasons4.
Lactate dehydrogenase (LDH) is an enzyme with a ubiquitous
expression5. It is responsible for catalyzing the anaerobic,
nicotinamide adenine dinucleotide phosphate-dependent
conversion of pyruvate to lactate, which is important during
times of high muscular activity6. Serum CK and LDH levels were
previously used as biomarkers to diagnose myocardial infarction.
Because of low specificity, however, they have been replaced by
troponin T and troponin I7, measured through high-sensitivity
assays8.
The heritability of LDH levels has been estimated between 40
and 50% (refs 9,10) and upwards of 38% for CK (ref. 11). Our
own data indicates a 19.33 and 19.36% heritability for CK and
LDH, respectively. A recently published genome-wide association
study (GWAS) of 3,232,779 imputed variants in 3,412 statin users
found two missense variants affecting serum CK levels, one in
CKM (rs11559024) and one in LILRB5 (rs12975366) (ref. 12).
An association of a variant in CD163 (rs7136716) with serum CK
levels has also been reported13. To date, no systematic GWAS has
been carried out to search for sequence variants influencing
serum LDH levels.
To search for common and rare variants that associate with CK
or LDH levels, we tested variants detected in a large sequencing
study in Iceland for association with these traits14. This unbiased
approach has the potential to uncover previously unexpected
molecular mechanisms regulating levels of this enzyme in serum.
A thorough understanding of sequence variants influencing these
biomarkers is important to improve the usefulness of their
measurements, and in the assessment of tissue damage15.
Results
Summary of findings. To search for sequence variants associat-
ing with mean serum levels of CK and/or LDH, we analysed
28.3 million variants, initially identified through whole-genome
sequencing of 2,636 Icelanders and subsequently imputed into
chip-typed individuals through long-range haplotype phasing16.
Genotype probabilities were calculated for first and second-degree
relatives of chip-typed individuals17. We tested for association
between sequence variants and serum CK in 63,159 individuals
(35,623 chip-typed and 27,536 with chip-typed first or second-
degree relatives), and serum LDH in 98,585 individuals (52,581
chip-typed and 46,004 with chip-typed first- or second-degree
relatives).
We used methodology outlined by Sveinbjornsson et al.18
to determine weighted genome-wide significance thresholds
for different variant classes based on the total number
of variants tested per class: loss-of-function (N¼ 6,476;
P¼ 2.6 10 6); missense (N¼ 100,502; P¼ 1.7 10 7); and
other (N¼ 23,854,999; P¼ 7.0 10 10).
We found a total of 13 variants associated with CK, and 16
associated with LDH. Of those, four were associated with both
enzymes (Table 1, Figs 1 and 2). In total, all of the reported
sequence variants explain 1.9% of CK variance, and 1.8% of LDH
variance. Our results include replication of variants in CKM,
LILRB5 and CD163 reported in GWASs of serum CK levels12,13.
None of the variants showed more significant associations when
alternate inheritance models were tested (Supplementary Tables 2
and 3), and no additional variants were detected using these
models.
Eleven of the variants are common (minor allele frequency
(MAF)45%), eight are of low frequency (MAF¼ 0.5-5%) and
five are rare (MAFo0.5%). Five loci contain several independent
signals, associating with either one or both of the enzymes
measured (Fig. 3). For loci with multiple signals, we present P
values and effects before and after adjusting for other significant
markers at that locus (Table 1). All variants correlated (r240.6)
with the variants we report are shown in the Supplementary
Data 1 and Supplementary Figs 5–33.
Most of the suspected genes are implicated in immune/
inflammatory response, enzyme clearance or muscular function,
but two encode subunits of the enzymes measured (cis signals)
and one encodes a protein that affects rates of CK clearance from
plasma.
Cis signals. We observed variants in CKM and LDHA, genes that
encode subunits of CK and LDH, respectively, with minor alleles
that associate with a lower level of their corresponding serum
enzyme levels. Enzymatic levels were measured by assessing
quantity through enzymatic activity. Our results, therefore,
indicate that these sequence variants act to either decrease the
amount of the enzyme produced, or their catalytic ability.
CKM. Through a stepwise conditional analysis at 19q13.3, we
found that four independent missense variants in CKM associate
with serum CK levels. With one of these, rs11559024 [C]
(MAF¼ 2.15%, Glu83Gly), we replicated a reported association12.
The associations of the remaining three low-frequency and rare
missense variants are novel. Minor alleles of all four CKM
variants have a large lowering effect on CK levels. We never
observed more than one of the minor alleles on the same
chromosome (all r2r2.2 10 4; Supplementary Table 4).
CKM encodes CK-M, one of two subunits of the CK dimer.
Three isoforms of the enzyme exist, consisting of different
combinations of CK-M and/or CK-B. Each isozyme has a unique
expression profile; CK-MM is expressed in skeletal muscle, CK-
MB in cardiac muscle and CK-BB in smooth muscle and the
brain19. CK-MM typically accounts for the majority of serum CK
(ref. 20).
LDHA. The missense variant rs116841148 [T] (MAF¼ 0.652%,
Ala147Ser) at 11p15.1 in LDHA associates with serum LDH levels
(Table 1). LDHA encodes the M subunit of the LDH enzyme,
expressed in all but one of the five isozymes of LDH (ref. 21).
CPN1. At 10q24.2, the low-frequency missense variant
rs61751507 [T] (MAF¼ 4.06%, Gly178Asp) in CPN1 associates
with lower CK levels (Table 1). CPN1 encodes carboxypeptidase
N. This protein is expressed in blood, hydrolyzes CK-MM10s
C-terminal lysine and converts CK-MM1, the enzyme‘s unaltered
form as expressed in tissue, into either CK-MM2 or CK-MM3.
This hydrolyzation alters CK-MM’s isoelectric point and half-life
without affecting properties such as enzymatic activity22,23. It is,
therefore, plausible that if the variant in CPN1 induces a change
in activity of carboxypeptidase N, it would affect CK-MM
clearance rather than having a direct effect on enzymatic activity.
Immune system genes associating with CK and/or LDH levels.
Seven loci harbouring variants associating with serum CK and/or
LDH levels have genes that are likely to be responsible for the
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associations that are involved in immune or inflammatory
response; CSF1, CD163/CD163L1, STAB1, CFH, LILRB5,
HLA-DQB1 and NINJ1. Three of these genes (CSF1, CD163 and
STAB1) have direct links to the clearance of products of cell
lysis from the serum through the mononuclear phagocytic
system (MPS) (refs 24–26). The remaining four implicated
genes do not have a known link to enzyme clearance, although
most are preferentially expressed in cells of the myeloid
lineage.
CSF1. At 1p13.3, the intronic variant rs333947 [A]
(MAF¼ 14.92%) in CSF1 associates with lower LDH levels
(Table 1). We observed no correlated coding variants (r240.6)
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Figure 1 | Manhattan plot showing the seven loci harbouring genome-wide significant signals influencing serum CK levels in the Icelandic population.
Variants are plotted by chromosomal position (x axis) and  log10 P values (y axis). P values above 1 10 25 are represented. Two loci (CKM and LILRB5)
harbour variants with P values below this cutoff (rs11559024: P¼ 1.8 10 115; rs12975366: P¼6.5 1044 and rs393600: P¼ 1.4 10 33). The red line
indicates the threshold for genome-wide significance, determined by the number of tests performed (P¼0.05/28.3 million¼ 1.8 109).
Table 1 | Summary of single marker associations for CK (N¼63,159) and LDH (N¼98,585) in Iceland.
Variant Allele
(min/maj)
MAF
(%)
Gene* CK LDH
Unadjusted Adjustedw Unadjusted Adjustedw
P value Effect
(Amin)
P value Effect
(Amin)
P value Effect
(Amin)
P value Effect
(Amin)
rs333947 A/G 14.92 CSF1 6.8 10 3 0.021 — — 2.8 10 10 0.042 — —
rs2274700 A/G 38.62 CFH 0.58 0.003 — — 4.1 10 12 0.034 — —
rs150956780z C/G 0.078 STAB1 0.60 0.05 — — 1.3 1061  1.526 — —
rs17412833z T/A 13.76 HLA-DQB1 1.5 104 0.032 — — 1.5 10 22 0.07 — —
rs12342201 A/G 49.45 NINJ1 0.70 0.002 — — 1.1 10 12 0.034 — —
rs61751507z T/C 4.06 CPN1 5.1 10 11 0.091 — — 0.34 0.011 — —
rs116841148z T/G 0.65 LDHA 0.17 0.049 — — 2.9 10 11 0.198 — —
rs7481951z A/T 37.45 ANO5 6.4 10 16 0.047 7.0 10 15 0.045 2.5 10 3 0.015 — —
rs137854526z C/T 0.24 ANO5 4.5 104 0.204 1.1 10 3 0.190 0.25 0.058 — —
chr11:22241070z A/T 0.27 ANO5 3.9 106 0.245 1.7 10 5 0.229 0.05 0.09 — —
rs2930191 A/G 37.22 — 2.3 104 0.021 — — 4.7 10 13 0.035 — —
chr12:7282745 TA/!TA 21.13 — 0.49 0.005 — — 1.2 10 25 0.064 2.3 10 12 0.043
rs145411783z A/C 0.66 CD163L1 0.90 0.005 — — 8.7 10 12 0.203 8.9 10 10 0.184
rs4072797z T/C 4.21 CD163L1 0.63 0.007 — — 9.9 1089 0.236 5.5 1085 0.239
rs117692263 C/T 9.31 CD163 1.2 10 17 0.083 1.2 10 11 0.067 6.1 1028 0.09 1.5 10 13 0.062
rs4883263z T/C 3.73 CD163 5.7 10 5 0.059 — — 1.8 10 19 0.114 1.4 106 0.063
rs7305678 T/G 16.16 — 3.0 1021 0.072 2.8 10 15 0.061 2.0 10 18 0.057 1.2 1023 0.069
chr12:110830276 C/T 2.09 — 2.9 104 0.071 — — 2.1 10 12 0.119 — —
rs7318906 A/G 47.08 — 2.7 10 13 0.041 — — 2.9 10 3 0.014 — —
rs149354459z G/C 0.21 CKM 6.0 10 20 0.55 2.8 1021 0.567 0.54 0.031 — —
rs145987658z A/G 0.086 CKM 8.9 109 0.59 2.1 109 0.611 0.58 0.047 — —
rs17357122z A/G 0.99 CKM 4.3 109 0.165 4.3 109 0.175 0.45 0.018 — —
rs11559024z C/T 2.15 CKM 1.8 10 115 0.446 1.1 10 117 0.45 0.16 0.023 — —
rs393600 G/A 25.17 LILRB5 1.4 10 33 0.079 1.3 109 0.046 1.6 1028 0.062 1.7 10 5 0.028
rs12975366z C/T 41.62 LILRB5 6.5 1044 0.08 4.7 10 20 0.061 7.0 10 51 0.074 4.1 1028 0.062
CK, creatine kinase; LDH, lactate dehydrogenase; MAF, minor allele frequency.
Variants showing significant association are in bold, based on the 25 variants tested (Po0.05/25¼ 2 10 3). Further information can be found in Supplementary Table 1.
*Genes given for intronic/exonic variants.
wAll variants are adjusted for all other significant variants in the same megabase.
zNon-synonymous coding variants.
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Figure 2 | Manhattan plot showing the 10 loci harbouring genome-wide significant signals influencing serum LDH levels in the Icelandic population.
Variants are plotted by chromosomal position (x axis) and  log10 P values (y axis). P values above 1 1060 are represented. One locus (CD163L1)
harbours a variant with P value below this cutoff (rs4072797: P¼9.9 10 89). The red line indicates the threshold for genome-wide significance,
determined by the number of tests performed (P¼0.05/28.3 million¼ 1.8 109).
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Figure 3 | Locus plots depicting variants at the LILRB5 locus associating with serum enzyme levels. Leading variants are labelled and shown in
purple, other variants are coloured according to correlation (r2) with the leading marker (legend at top-right).  log10 P values are shown along the left y
axis and correspond to the variants depicted in the plot. The right y axis shows calculated recombination rates at the chromosomal location, plotted as a
solid blue line. (a) Association between the signal represented by rs393600 and serum CK levels. (b) Association between the signal represented by
rs12975366 and serum CK levels. (c) Association between the signal represented by rs393600 and serum LDH levels. (d) Association between the signal
represented by rs12975366 and serum LDH levels.
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that could explain the association (Supplementary Data 1).
The position shows a high degree of evolutionary conservation
(GERP (ref. 27) ¼ 4.83; Supplementary Table 5). CSF1 encodes
human macrophage-specific colony stimulating factor, a cytokine
necessary for the differentiation of monocyte lineage cells,
including hepatic Kupffer cells (KCs) (ref. 24). In animal
models, reducing KC numbers affects serum enzyme levels,
including CK, LDH and aspartate transaminase (AST), without
evidence of skeletal or liver damage24. Rs333947 [A] also
associates with lower AST levels (Supplementary Table 6). We
also observed a suggestive association with CK levels. The
associations we observed are consistent with CSF1 function and
may indicate an increased macrophage activity, promoting faster
clearance of serum enzymes.
We assessed all sequence variants discussed in this paper for
associations with AST levels (Supplementary Table 6). Seven
variants, including rs333947, associate with AST based on the
number of tests performed (Po0.05/25¼ 2.0 10 3). The
direction of effect was always consistent; each allele either had
an increasing or decreasing effect on the levels of all enzymes it
associates with.
CD163/CD163L1. At 12p13.31, the region containing CD163
and its paralog CD163L1, we observed associations with CK and
LDH levels (Table 1). Two variants associated with both CK and
LDH levels and four only with LDH levels.
Two common variants associate with higher serum levels
of CK and LDH; the intergenic variant rs7305678 [T]
(MAF¼ 16.16), and the intronic rs117692263 [C]
(MAF¼ 9.31%). Three low-frequency missense variants in
the region associate solely with serum LDH levels; rs4072797
[T] (MAF¼ 4.21%, Asp588Asn) and rs145411783 [A]
(MAF¼ 0.66%) in CD163L1, and rs4883263 [T] (MAF¼ 3.73%,
Ile342Val) in CD163. Finally, a common intergenic indel
(chr12:7282745:0:TA MAF¼ 21.13%) associates with LDH levels.
CD163 encodes a scavenger receptor expressed on macro-
phages and monocytes, including KCs, that is responsible
for uptake of the haemoglobin–haptoglobin complex from the
bloodstream25. The CD163L1 gene, encoding the M160 receptor,
is closely related to CD163. The paralog is expressed by many of
the same cells and has a sequence that is highly similar to that of
CD163 (ref. 28), but does not have affinity for the same ligands as
CD163 (ref. 25).
Association of the intergenic variant rs7305678 with serum CK
levels replicates a previously published association between a
single marker, rs7136716 at the CD163 locus and serum CK levels
in the Japanese13. Rs7136716 correlates with rs7305678 in both
the Chinese/Japanese (r2¼ 0.8529) and Icelandic (r2¼ 0.75)
populations, but is independent of other signals we report in
the region.
STAB1. At 3p21.1, the very rare missense variant rs150956780
[C] (MAF¼ 0.078%, Val1522Leu) at a highly conserved site
within STAB1 (GERP (ref. 27)¼ 4.56) associates with drastically
lower serum LDH levels (effect¼  1.526SD) (Table 1). An
association signal was observed across a large region and
rs150956780 is more frequent outside of Iceland (Tuscany (TSI)
MAF¼ 1.0%, CEPH Utah (CEU) MAF¼ 0.6% (ref. 30);
Supplementary Table 5). This could reflect a recent introduction
of the sequence variant into the Icelandic population. STAB1
encodes stabilin-1, a transmembrane scavenger receptor expressed
in a number of tissues including activated macrophages26.
CFH. At 1q31.3, in a locus containing the CFH gene, the
synonymous variant rs2274700 [A] (MAF¼ 38.62%) associates
with lower LDH levels (Table 1). Rs2274700 is fully correlated
(r2¼ 1.00) with rs1410996 [A] (MAF¼ 38.58%). Rs1410996 is
one of a large number of sequence variants within genes of the
complement system reported to associate with age-related
macular degeneration31,32. In our data, the [A] allele associates
with lower risk of associate with age-related macular
degeneration. Mutations in CFH have also been shown to cause
both atypical haemolytic uraemic syndrome33. CFH encodes
complement factor H (FH), a key regulator of the alternative
pathway of the complement system, produced and secreted in
abundance by KCs34. FH also binds to long pentraxin 3 (PTX3)
through two of FH’s SCR domains (SCR7 and SCR19-20)35.
PTX3 influences the regulation of the complement system36 and
plays a non-redundant role in the orchestration of tissue repair
and remodelling37. FH’s specific functions and its associations
suggest that alterations of enzyme levels occur through
modulation of complement activation or tissue repair and
remodelling38.
LILRB5. At 19q13.42, a locus containing LILRB5, we observed
associations of two common and modestly correlated (r2¼ 0.24)
sequence variants with CK and LDH levels. The strongest signal is
a missense variant rs12975366 [C] (MAF¼ 41.62%, Asp247Gly,
Asp147Gly) that associates with lower levels of both CK and
LDH. A second marker, the intronic variant rs393600 [G]
(MAF¼ 25.17%) in LILRB5, similarly associates with both CK
and LDH levels. LILRB5, encoding leukocyte immunoglobulin-
like receptor subfamily B member 5, belongs to the LILR class of
genes expressed on cells of myeloid lineage, and is involved in
inhibition of inflammatory responses39,40. Showing association of
the marker rs12975366 with CK at LILRB5 replicates previous
findings12.
HLA-DQB1. In the human leukocyte antigen (HLA) region at
6p21.3, the best association signal with LDH levels is represented
by the missense variant rs17412833 [T] (MAF¼ 13.76%,
Phe119Tyr) in HLA-DQB1. The alleles of the different HLA
genes are strongly correlated to each other and often discussed as
long haplotypes41. The HLA genes control the adaptive immune
response through presentation of antigens to T cells42. We tested
imputed HLA alleles of six of the classical HLA genes: HLA-A;
HLA-B; HLA-C; HLA-DQA1; HLA-DQB1; and HLA-DRB1 for
association43. The HLA molecular type associating most strongly
with serum LDH is HLA-DQB1*06:04 (r2¼ 0.53). We note that
the [T] allele of rs17412833 is present in the following imputed
HLA molecular types: DQB1*05:01; 05:02; 05:03; 06:04; and
06:09. HLA-DQB1 forms a part of the dimeric HLA-DQ
molecule44. HLA-DQB1*06:04 has previously been implicated
in myasthenia gravis in the Chinese45 as well as cervical
dystonia46. Conditional analysis shows that the HLA-
DQB1*06:04 signal is fully explained by the missense variant
rs17412833, but indicates that the association of rs17412833 is
not explained by the HLA-DQB1*06:04 signal.
NINJ1. At 9q22.31, the common intron variant rs12342201 [A]
(MAF¼ 49.45%) in NINJ1 associates with lower LDH levels
(Table 1). NINJ1 encodes the ninjurin-1 protein, an adhesion
molecule reported to be upregulated in myeloid cells during
inflammation and important in immune cell migration following
neuronal injury47. NINJ1 expression is ubiquitous, and it has been
implicated in liver function and hepatocellular senescence48.
Muscle-linked genes associating with CK and/or LDH levels.
Variants at two loci are coding variants in genes that are
preferentially expressed in muscle and play a role in its function.
ANO5. At 11p14.3, we observed three variants in ANO5 that
associate with serum CK levels. The common missense
variant rs7481951 [A] (MAF¼ 37.45%, Leu322Phe) associates
with lower serum CK levels. The remaining two rare variants, the
missense variant rs137854526 (MAF¼ 0.24%, Phe578Ser),
and the nonsense variant chr11:22241070:S (MAF¼ 0.27%,
Cys601X), associates with higher CK levels (Po0.05/15 non-
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synonymous¼ 3.3 10 3). Rs137854526 occurs at a highly
conserved site (GERP (ref. 27) ¼ 5.69). ANO5 encodes the
protein anoctamin-5, a chloride channel in the endoplasmic
reticulum membrane49, expressed mainly in skeletal and cardiac
muscle. Variants in the gene, including these two rare mutations,
have been reported to cause limb-girdle muscular dystrophy,
which primarily affects skeletal muscle but often presents with
cardiac pathologies50,51. Chr11:22241070:S shows suggestive
association with heart failure (effect¼ 1.629, P¼ 1.0 10 3,
N¼ 11,374 cases).
Two cases of compound heterozygotes for ANO5 mutations
presenting with skeletal muscle dysfunction and cardiac abnorm-
alities have been described in the literature49,52. We support this
with a further two homozygotes for rare ANO5 mutations
presenting with cardiovascular phenotypes. Firstly, an individual
homozygous for rs137854526 and, secondly, an individual
homozygous for chr11:22241070, both presenting with several
cardiovascular phenotypes (Supplementary Table 7). These
findings provide further evidence for the effect of ANO5
variants on dysfunctions of the heart.
We note another coding variant in a gene specifically expressed
in muscle has a P value just above the significance threshold.
The common missense variant in CACNG1 rs1799938 [A]
(MAF¼ 10.64%, Gly196Ser) suggestively associates with CK
levels (P¼ 3.2 10 7; effect¼ 0.046). CACNG1 encodes the g
subunit of a 1,4-dihydropyridine (DHPR) -sensitive calcium
channel, preferentially expressed in skeletal muscle53.
Other signals associating with CK and/or LDH Levels. The
three remaining association signals are at loci without any
obvious causative gene.
We observed a signal at 11p11.2 associating with lower serum
LDH levels, represented by a large group of 276 correlated
markers (r240.6; Supplementary Data 1). The marker showing
the strongest association is the common intergenic variant
rs2930191 [A] (MAF¼ 37.22%).
At 12q24.13, the low-frequency variant chr12:110830276:S
(MAF¼ 2.09%) associates significantly with lower LDH levels,
and suggestively with CK levels.
Finally, at 13q22.1, the common variant rs7318906 [A]
(MAF¼ 47.08%) associates with decreased CK levels.
We used GTEx Portal’s eQTL Browser to assess whether any of
our reported variants affected gene expression. None of the 25
markers we discussed in the current study was directly reported
or correlated (r240.2) to any GTEX cis-eqtl (Po1 10–5).
Signals observed specifically in statin takers. We examined
statin usage, stratifying our CK and LDH measurements by statin
intake. Prescription data for statins were available for a period of
time ranging from 2003 to 2009 and the stratified analysis
therefore only included blood measurements from this interval.
No additional signals were detected (Supplementary Figs 1–4).
Our data showed no indication of the overall results being driven
by individuals treated by statins, or any genetic susceptibility to
statin side effects, for any of the loci in question (Supplementary
Tables 8 and 9). Furthermore, the reported variant rs4363657 in
SLCO1B1 showed no effect on any of the tested phenotypes
(Supplementary Table 10).
Advantages of whole-genome sequencing. For the 25 reported
variants, twenty were present in the 1000G data set
(Supplementary Table 11). Of these, three could not be imputed,
and a further three showed very low correlation (r2o0.64)
between the directly typed and the 1000G imputed phenotypes.
Fourteen variants showed high correlation between directly typed
and imputed genotypes (r2Z0.8) and could therefore plausibly
have been discovered using only 1000G imputation.
Five variants were not present in 1000G, but had correlates
(r240.6) within the data set (Supplementary Table 12). Of these,
four showed good correlation (r240.6) between imputed
and correlated genotypes, and could, therefore, have shown
association with CK or LDH levels in a study relying purely on a
1000G imputation data set.
We therefore report seven variants that could not have been
discovered using a 1000G imputation set.
Discussion
Elevation of serum enzyme levels can be a result of two separate
processes; increased leakage from tissue into the serum, or
reduced clearance54. Furthermore, observations of altered serum
enzyme levels can result from a change in enzymatic activity.
We report variants affecting serum enzyme levels through all
three mechanisms.
Our discovery of a high number of genes linked to immune
response is consistent with the MPS’s role in clearing debris
and foreign material from the bloodstream, including
through receptor-mediated endocytosis of short-lived cellular
enzymes55,56. Although the MPS has been implicated, the specific
receptors responsible for uptake of serum enzymes have not yet
been identified24. Nonspecific receptors, responsible for uptake of
several enzymes, have been postulated24,57. We report a number
of variants in genes expressed preferentially in phagocytic cells,
notably hepatic KCs, which affect levels of serum enzymes. The
protein products encoded by CD163 and STAB1, and LILRB5 are
all scavenger receptors expressed by macrophages58,59, and could
be the unidentified receptors responsible for endocytosis of serum
enzymes by cells of the MPS.
Non-synonymous variants in ANO5 associates with serum CK
levels, consistent with the fact that serum CK levels are largely
influenced by leakage of CK from damaged myocytes60.
The results of this study underscore the diversity in sources of
variation of serum enzyme levels, each of which are influenced by
sequence variants, and must be kept in mind when interpreting
the measurements.
Methods
Population. Measurements of serum CK levels were available for a total of 63,159
Icelanders. Of these, 35,623 were genotyped using Illumina chips and imputed
using long-range-phased haplotypes. Genotype probabilities were calculated for
27,536 individuals based on genetic information available for first and second-
degree relatives. Measurements of serum LDH levels were available for a total of
98,585 individuals, 52,581 of whom were chip-typed using Illumina chips, and
46,004 of whom had genotype probabilities calculated. All individuals had provided
consent, and the study was approved by the Data Protection Commission of
Iceland and the Icelandic National Bioethics Committee.
Stratification by statin intake. CK and LDH measurements were stratified
by statin intake. CK measurements were available for 8,900 statin takers
(CKon statin¼ 5,207; CKoff statin¼ 6,877), and LDH measurements were available for
9,851 statin takers (LDHon statin¼ 6,266; LDHoff statin¼ 6,877), respectively, with an
overlap of 7,534 individuals. These cohorts were used to test sequence variants for
association with serum enzyme levels during and outside of times of statin use.
Serum enzyme measurements. Serum enzyme measurements were obtained
from three laboratories in Iceland: The Laboratory of the Icelandic National
University Hospital; The Icelandic Medical Center Laboratory in Mjodd; and
Akureyri Hospital. We used measurements of serum CK (N¼ 63,159, geometric
mean¼ 211.1), and LDH (N¼ 98,585, geometric mean¼ 113.1). Additional
measurement characteristics can be found in Supplementary Table 13. Serum levels
were adjusted for sex, age and laboratory of origin. When multiple measurements
were available for an individual, the mean adjusted value was used.
Whole-genome sequencing and Illumina single-nucleotide polymorphism chip
genotyping. The process used to whole-genome sequence the 2,636 Icelanders,
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and the subsequent imputation from which the data for this analysis were gener-
ated has been extensively described in a recent publication14.
Association analysis. All serum enzyme measurements were corrected for age,
sexand laboratory of origin, and were subsequently standardized to have a normal
distribution. To test for association between quantitative traits and sequence
variants, a generalized form of linear regression was used (see Supplementary
Note 1). The quantitative trait was used as the response variable and the expected
allele count (gene dosage) as the covariate.
In the regression analysis of CK/LDH, we used genealogy information and
assume a variance covariance matrix proportional to the kinship matrix (see
Supplementary Note 1). To account for relatedness and stratification within the
case and control sample sets, we applied the method of genomic control61. The
inflation factor lg of the w2 statistics was estimated on the basis of a set of about
300,000 common variants distributed across the genome, and P values were
adjusted by dividing the corresponding w2 values by this factor. The genomic
control was calculated to be l¼ 1.16 for CK and 1.22 for LDH (Supplementary
Figs 34 and 35).
Significance thresholds. Sequence variants were weighted according to their prior
probability of affecting gene function. Thresholds for genome-wide significance
were applied, depending on variant class, as described by Sveinbjornsson et al.18.
The type I error rate of 0.05 was allocated equally between three classes of variants;
loss-of-function (N¼ 6,476), missense (N¼ 100,502) and other variants
(N¼ 23,854,999). This yielded class-specific Bonferroni genome-wide significance
thresholds of 2.6 10 6, 1.7 10 7 and 7.0 10 10, respectively.
Sanger sequencing and reimputation. Two sequence variants were poorly
imputed due to a low number of sequenced carriers in the original Icelandic data
set. A group of suspected carriers and non-carriers of the missese variants
rs145987658 in CKM (info¼ 0.63) and rs150956780 in STAB1 (info¼ 0.58) were
Sanger sequenced, and reimputation was subsequently carried out. Imputation
information following reimputation increased for both variants.
Fraction of variance explained. Fractions of CK and LDH variance explained by
the reported variants were calculated using the formula 2f (1 f) a2, where
f¼MAF and a¼ effect.
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